OraLiva
OraLiva Inc. is a diagnostics company pioneering early cancer detection with a non-invasive, AI-powered cytology platform. Their proprietary technology analyzes single-cell data from a simple brush sample to detect cellular warning signs of dysplasia in real time, providing dental providers with lab-grade accuracy. The platform, ONC INCYT, is scalable and designed for point-of-care use, initially targeting oral cancer but with potential applications across multiple epithelial cancers. Backed by over two decades of NIH-funded research and led by experts in biomedical diagnostics, OraLiva aims to transform cancer screening by enabling earlier detection and intervention, reducing treatment costs and improving survival rates.
OraLiva
OraLiva Inc. is a diagnostics company pioneering early cancer detection with a non-invasive, AI-powered cytology platform. Their proprietary technology analyzes single-cell data from a simple brush sample to detect cellular warning signs of dysplasia in real time, providing dental providers with lab-grade accuracy. The platform, ONC INCYT, is scalable and designed for point-of-care use, initially targeting oral cancer but with potential applications across multiple epithelial cancers. Backed by over two decades of NIH-funded research and led by experts in biomedical diagnostics, OraLiva aims to transform cancer screening by enabling earlier detection and intervention, reducing treatment costs and improving survival rates.
TL;DR
What they do: AI-powered, non-invasive cytology platform (brush biopsy + microfluidics + deep-learning) for early detection of oral dysplasia and cancer (ONC InCyt).
Founded: 2019
Headcount: 11 employees
Funding: $2.0M seed + NIH/NSF grants (includes $1.9M NIDCR Direct to Phase II SBIR)
Origins: Spun out of McDevitt Lab at NYU based on ~20 years of NIH-funded research
Company Overview
Problem Domain
Early cancer detection in oral and other epithelial tissues via non-invasive cytology.
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
$2,000,000
Described as an oversubscribed seed round with participation from DCVC, RTP Angel Fund, and NYU Innovation Venture Fund.
$1,900,000
NIDCR (NIH) Direct to Phase II SBIR award supporting development of AI-linked cytomics-on-a-chip.
Investor Signal
“Seed led by angel Preetpal Sidhu with participation from DCVC, RTP Angel Fund, and NYU Innovation Venture Fund; company has multiple NIH/NSF non-dilutive grants.”